Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake
Official title: Evaluation of Ultralow Dose PET Imaging for Detecting SSTR2 Radiotracer Uptake
Run by Nuclear Imaging Institute · NCT07284589 · Data updated 2026-11-12
This study will test whether an ultralow-dose 68Ga-Dotatate PET scan on a high-sensitivity scanner can detect SSTR2 uptake in adults with and without neuroendocrine tumors.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 120 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Nuclear Imaging Institute Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Englewood, New Jersey) |
| Status | Recruiting |
| Started | December 11, 2025 |
| Main results expected | April 30, 2030 |
| Study ends | April 30, 2030 |
| Registry record updated | April 8, 2026 |
| Trial ID | NCT07284589 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who can give informed consent, are not pregnant or breastfeeding, and either have a known or suspected neuroendocrine tumor or are healthy volunteers willing to undergo PET imaging and follow study rules are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, unable to tolerate a prolonged scan (severe claustrophobia or mobility limits), those who have exceeded annual research radiation limits, or those currently on SSTR-targeted therapies are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants will receive a very small amount of the FDA-approved radiotracer 68Ga-Dotatate (less than about 1/20th of the standard dose) and be imaged on a new high-sensitivity PET scanner for up to three hours. Investigators will vary injection-to-scan timing, scan duration, and image reconstruction methods to determine how low the radiation dose can be reduced while preserving image quality. The study will enroll roughly 200 adults, including healthy volunteers and people with neuroendocrine tumors, and will compare tracer uptake patterns across groups. Outcomes will focus on image quality and ability to detect SSTR2-expressing lesions at ultralow doses.
Why it matters
Potential benefit: If successful, this technique could allow much lower-radiation PET scans that enable safer and more frequent imaging for detection and treatment monitoring of neuroendocrine tumors.
How similar studies have gone: Standard-dose 68Ga-Dotatate PET is well established for neuroendocrine tumors, and small pilot studies using high-sensitivity scanners and reduced tracer doses have shown promise, but ultralow-dose reductions of 10–100x remain largely unproven in large cohorts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years. * Ability to provide informed consent and comply with study procedures. * For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential. Exclusion Criteria: * Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \[mSv\] total). * More than four prior enrollments in this study. * Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan * Medication \& Prior Treatment Exclusions: SSTR targeted therapies * Pregnant or breastfeeding individuals (negative pregnancy test required) * Inability to provide informed consent * Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
Where it's running
-
Nuclear Imaging Institute
Englewood, New Jersey, United States Recruiting
Study contacts
- Study coordinator: Barbara Blanchfield
- Email: bblanchfield@nii.org
- Phone: 9732554955
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
External validation of the TB-NET score in advanced well‑differentiated neuroendocrine tumors
This study tests whether the TB-NET score can predict progression-free survival in adults with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors or lung carcinoids who have received systemic therapy.
-
Accessory breathing muscles in people with chronic neck pain
This study compares how accessory chest and neck muscles work in people with chronic neck pain vs. healthy individuals to see how they relate to diaphragm function and overall breathing.
-
Multiomic data study in South Carolina Medicaid patients with Type 2 diabetes and healthy controls
This study tests whether combining genetic, molecular, clinical, wearable, and lifestyle data in SC Medicaid patients with Type 2 diabetes, and in healthy controls, can help predict kidney disease and diabetes progression.
-
Effects of exogenous ketones on brain energy and thinking in older adults with prediabetes
In older adults with prediabetes, researchers will test if a single dose of a ketone supplement can boost brain energy use and processing speed compared with people with normal blood sugar.
-
Safety and tolerability testing of VVZ-2471 in healthy adults
This study tests whether VVZ-2471 is safe and tolerable in healthy adults who don’t use illicit drugs.
-
Immediate effects of graded motor imagery for chronic ankle instability
This trial will test whether graded motor imagery produces quick improvements in pain, muscle strength, stiffness, function, and perceived stability for adults with chronic ankle instability compared with healthy people.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.